Peptides DB
Research-centric peptide and protocol reference hub
Study 32 of 33Tirzepatide literatureArthritis & rheumatology (Hoboken, N.J.) · RCT2026

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.

The combination of ixekizumab and tirzepatide showed significant improvements in disease control and weight reduction in adults with psoriatic arthritis compared to ixekizumab alone.

Read at Arthritis & rheumatology (Hoboken, N.J.)Add to compare

Where it sits

this study against the rest of the tirzepatide corpus
4
Preclinical
21
Observational
1
Open-label
4
Randomised · this one
3
Reviews

Summary and findings

This study evaluated the efficacy and safety of ixekizumab (IXE) combined with tirzepatide (TZP) versus IXE alone in adults with active psoriatic arthritis (PsA) and overweight or obesity. The primary endpoint was achieved with significant improvements in the IXE + TZP group compared to IXE alone. No new safety concerns were reported.

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →
31.7% IXE + TZP vs 0.8% IXE alone at 36 weeks, P<0.001.2026

Abstract

The authors’ words, as Arthritis & rheumatology (Hoboken, N.J.) supplied them

<h4>Objective</h4>Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight-related comorbidity or obesity.<h4>Methods</h4>TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP. The primary end point was simultaneous achievement of 50% improvement in American College of Rheumatology response criteria (ACR50) and ≥10% weight reduction at 36 weeks. Key secondary outcomes included ACR50. Additional secondary outcomes and patient-reported outcomes (PROs) were assessed. Safety was assessed as adverse events (AEs), treatment-emergent AEs, and serious AEs.<h4>Results</h4>A total of 271 participants were randomized (IXE + TZP, n = 138; IXE, n = 133). The primary end point was achieved with significant improvements in the IXE + TZP arm (31.7%) compared to IXE alone (0.8%) (P < 0.001). Greater improvements in ACR50 were demonstrated in IXE + TZP (33.5%) versus IXE alone (20.4%) (P = 0.02), with significant early separation at week 4 (nominal P < 0.05). IXE + TZP demonstrated nominally significant improvements in ACR20 (P < 0.001), minimal disease activity (P < 0.05), and absolute Psoriasis Area and Severity Index score (P < 0.01) compared to IXE alone. IXE + TZP demonstrated significant improvements in PROs, including Health Assessment Questionnaire-Disability Index (∆ -0.2; nominal P < 0.001) and Functional Assessment of Chronic Illness Therapy-Fatigue (improvement of 3.8; nominal P < 0.01) compared to IXE alone. Safety profiles were consistent with previous studies for each drug.<h4>Conclusion</h4>Participants with active PsA and complex inflammatory-metabolic disease achieved clinically meaningful improvement of PsA, physical function, weight reduction, and quality of life when treated with IXE + TZP compared to IXE alone, with no new safety concerns.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Tirzepatide corpus

BCardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes.American heart journal plus : cardiology research and practice · 2026 · n=11330 · 19.5% 5-point MACE for semaglutide vs 17.1% for tirzepatide, HR 1.03, 95% CI 0.94-1.12.HumanBTirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026 · Odds ratio: 3.69, 95% confidence interval: 2.21-6.16; P < .001.HumanCEnsemble-Based Segmental Helical Organization in an Aib-Rich Lipidated Peptide: Biomacromolecular Insights from High-Field NMR.Biomacromolecules · 2026 · Not reported in abstract.In vitroB12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study.Obesity pillars · 2026 · n=249 · Mean weight loss was 19.9 ± 8.6% at 12 months.HumanBReal-world, digital-first delivery of GLP-1 receptor agonist therapy in women.Nature medicine · 2026 · Mean weight reduction was 16.1 kg (95% CI 15.9 to 16.2; P < 0.001).HumanAEvaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.Obesity pillars · 2026 · Mean weight regain from nadir to Week 176 was 3.8 kg for 5 mg, 4.4 kg for 10 mg, and 3.7 kg for 15 mg.Human